EActivity - Module 1: Spotlight on Achieving Remission and Monitoring Disease Progression

Title:

EActivity - Module 1: Spotlight on Achieving Remission and Monitoring Disease Progression

Topic: Rheumatology
Relevant Terms: American College Of Rheumatology, Disease Activity Measures, DMARDs, Rheumatoid Arthritis, Treat-to-target
Primary Audience: Generalists, Nurse Practitioners, Physician Assistants, Primary Care Physicians, Rheumatologists
Launch Date: 25-Jul-12
Credits: AMA PRA Category 1 Credit
Expiration Date: The accreditation for this activity has expired.

Learning Objectives

After completing this activity, the participant will demonstrate the ability to:

  1. Evaluate the challenges of achieving remission for patients with RA
  2. Apply a practical approach to monitor RA disease progression

    Faculty

    Neal S. Birnbaum, MD
    Director, Division of Rheumatology
    California Pacific Medical Center
    San Francisco, CA
    Brian R. Kaye, MD, FACP
    Clinical Professor of Medicine
    University of California San Francisco
    Attending Physician
    Alameda County Medical Center
    Oakland, CA
    Eric M. Ruderman, MD
    Professor of Medicine
    Feinberg School of Medicine
    Clinical Practice Director
    Rheumatology Clinic
    Northwestern Department of Medicine
    Northwestern University
    Chicago, IL
    Improving RA Outcomes: An Update on Current Strategies and Evolving Therapies
    Module 1: Spotlight on Achieving Remission and Monitoring Disease Progression
     
    Jointly sponsored by the Annenberg Center for Health Sciences at Eisenhower and Impact Education, LLC in collaboration with Postgraduate Institute for Medicine
       
     
    Release date: July 25, 2012
    Expiration date: January 31, 2014
     
    Supported by an independent educational grant from Abbott.


    This activity is supported by an educational donation provided by Amgen.


    Target Audience

    This activity has been designed to meet the educational needs of specialists, generalists, physician assistants, nurse practitioners, and other health care professionals who diagnose, treat, and manage patients with rheumatoid arthritis (RA).

    Statement of Need
    The advent of biologic agents has created hope for many patients suffering from RA. However, because of the difficulty in sustaining remission, patients are frequently switching from one agent to another creating a myriad of factors influencing outcomes including compliance, cost, and continuity of care. As such, many clinicians do not adhere to the ACR RA treatment guidelines by sequencing therapies in patients who are incomplete or non-responders to treatment. Further compounding clinical outcomes is a lack of validated methods to appropriately measure disease progression. New therapies and treatment strategies on the horizon have the potential to address existing practice gaps if physicians can become competent in their ability to apply these new developments for their patients with RA. To help meet this educational need, this activity will review the data on new therapeutic targets along with the science underlying the mechanism of action and distinction from existing therapies.

    Accreditation Statement

    This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the Annenberg Center for Health Sciences at Eisenhower and Impact Education, LLC. The Annenberg Center for Health Sciences at Eisenhower is accredited by the ACCME to provide continuing medical education for physicians.

    Annenberg Center for Health Sciences at Eisenhower
    www.annenberg.net
     
    Credit Designation
    The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
     
    Disclosure of Conflicts of Interest
    The Annenberg Center for Health Sciences at Eisenhower (Annenberg Center) assesses conflict of interest with its instructors, planners, managers and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by the Annenberg Center for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. The Annenberg Center is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
     
    The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
     
    Name of Faculty or Presenter
    Reported Financial Relationship
    Neal S. Birnbaum, MD
    Fees for Non-CME/CE Services: Amgen Inc., Pfizer Inc., Abbott Pharmaceuticals, and Centocor Ortho Biotech.
    Brian R. Kaye, MD, FACP
    Consulting Fees: UCB Pharma
    Fees for Non-CME/CE Services: Pfizer Inc., Forest Pharmaceuticals, Abbott Pharmaceuticals, Warner-Chilcott, and Takeda Pharmaceuticals
    Eric M. Ruderman, MD
    Consulting Fees: Abbott Pharmaceuticals, Amgen, Inc., Bristol-Myers Squibb, CVS/Caremark, Genentech/Roche, Eli Lilly and Company, and Pfizer, Inc.
    Contracted Research: Abbott Pharmaceuticals, Pfizer, Inc.
     
    The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
     
    The following planners and managers, Laura Excell, ND, NP, MS, MA, LPC, NCC; Trace Hutchison, PharmD; Samantha Mattiucci, PharmD, CCMEP; Jan Schultz, RN, MSN, CCMEP; Patricia Staples, MSN, NP-C, CCRN and Gordon West, PhD, CCMEP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
     
    Steven Casebeer, MBA
    Has nothing to disclose.
     
    Method of Participation and Request for Credit
    There are no fees for participating and receiving CME credit for this activity. During the period July 25, 2012 through January 31, 2014, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) successfully complete the embedded questions within the activity; 4) and complete the evaluation form. Upon completion of the full CME/CE activity, your certificate will be made available immediately to download and print.
     
    Media
    Internet
     
    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Annenberg Center, Postgraduate Institute for Medicine (PIM), Impact Education, LLC and commercial grantors do not recommend the use of any agent outside of the labeled indications. 
     
    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the Annenberg Center, PIM, Impact Education, LLC, and commercial grantors. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
     

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

    Estimated time to complete activity:
    1 Hour

    Course Viewing Requirements
    PC      
    Internet Explorer (v7 or greater), Google Chrome or Firefox        
    MAC
    Safari, Google Chrome or Firefox
     
     
    PI-CME Opportunity
    This online module is linked to a Performance Improvement CME (PI-CME) activity. Participating in this PI-CME will provide you with up to 20 CME credits. The platform that has been developed specifically for this program makes it easy for you to enter patient data based on 5 quality indicator measures. These measures, developed by the American College of Rheumatology, the National Committee for Quality Assurance and the Physician Consortium for Performance Improvement, are designed for individual quality improvement. The measures include: Tuberculosis Screening, Periodic Assessment of Disease Activity, Functional Status Assessment, Assessment and Classification of Disease Progression, and Glucocorticoid Management.
     
    Instructions for participating in the PI-CME activity and obtaining CME Credit
    You can receive up to 20 AMA PRA Category 1 Credits™. You earn credit as you complete the various activities; however, in order to earn the full 20 AMA PRA Category 1 Credits™, you must complete the stages in the order presented, and in the timeline presented.
     
    For completing
     
    You will receive
    Stage A  - practice assessment and patient record reviews
    5 AMA PRA Category 1 Credits™
    Upon successful completion of Stage A, you will receive an email directing you to the Stage B modules listed below
    Stage B -  successful completion of at least one of the following two CE modules:
    Module 1: Spotlight on Achieving Remission and Monitoring Disease Progression
    Module 2: Spotlight on New Treatments and the Impact of Unique Patient Characteristics on Disease Remission


    5 AMA PRA Category 1 Credits™
    Stage C  - follow-up practice assessment and patient record reviews
    5 AMA PRA Category 1 Credits™
    Completion of all three stages (Stage A – C) in the order presented
    (includes 5 additional credits for completion of all 3 stages)
    Total of 20 AMA PRA Category 1 Credits™
     
    Go to the PI-CME Activity Stage A:
    www.impactedu.net/RAPICME
    (copy and paste link into your web browser)
     
    Select the button below to begin Module 1: Spotlight on Achieving Remission and Monitoring Disease Progression